AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16246928 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially fluoridated hard water
Number of subjects: 0
Study 16246928 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference water
Number of subjects: 0
Study 11102253 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 166
Study 11102253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 11102253 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 166
Study 9285660 — intervention group
Group type: EXPERIMENTAL
Intervention: COER verapamil
Number of subjects: 257
Study 9285660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 8301153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 million units (mU) of Betaseron
Number of subjects: 30
Study 8301153 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 million units (mU) of Betaseron
Number of subjects: 30
Study 8301153 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 million units (mU) of Betaseron
Number of subjects: 30
Study 8301153 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 million units (mU) of Betaseron
Number of subjects: 30
Study 8301153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (WHO Standard)
Number of subjects: 30
Study 3510847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 178
Study 3510847 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 178
Study 3510847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 178
Study 3510847 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 178
Study 2646187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of tablets containing 3 mg of prostaglandin E2
Number of subjects: 345
Study 2646187 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous onset of labor awaited until the 42nd week of pregnancy
Number of subjects: 345
Study 31882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (apo B) levels
Number of subjects: 4623
Study 31882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo B discordance relative to LDL-C
Number of subjects: 4623
Study 31882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo B discordance relative to non-HDL-C
Number of subjects: 4623
Study 31882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo B
Number of subjects: 4623
Study 29902969 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided propofol administration (target range 40-60)
Number of subjects: 240
Study 29902969 — intervention group
Group type: COMPARATOR
Intervention: Weight-related propofol administration (2 mg/kg)
Number of subjects: 240
Study 29902969 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided propofol administration
Number of subjects: 240
Study 29902969 — intervention group
Group type: COMPARATOR
Intervention: Weight-related propofol administration
Number of subjects: 240
Study 28260153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet used from the beginning of osteotomy to the completion of arthroplasty (Group C)
Number of subjects: 150
Study 28260153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet used from the beginning of operation to the completion of joint replacement (Group B)
Number of subjects: 150
Study 28260153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet used during the entire operation (Group A)
Number of subjects: 150
Study 26287881 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with concurrent high-fluence CXL
Number of subjects: 140
Study 26287881 — intervention group
Group type: COMPARATOR
Intervention: Standard LASIK (LASIK-only)
Number of subjects: 140
Study 26287881 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LASIK-CXL and LASIK-only
Number of subjects: 140
Study 23442755 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 154
Study 23442755 — intervention group
Group type: COMPARATOR
Intervention: Low-dose progestin treatment (2.5 mg/day norethisterone acetate)
Number of subjects: 154
Study 23442755 — intervention group
Group type: COMPARATOR
Intervention: Low-dose progestin treatment
Number of subjects: 154
Study 21394001 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal infusion of 0.1% ropivacaine (5 ml/h for 6 hours)
Number of subjects: 11
Study 21394001 — intervention group
Group type: COMPARATOR
Intervention: Repeated hourly bolus doses of 0.1% ropivacaine
Number of subjects: 11
Study 21394001 — intervention group
Group type: COMPARATOR
Intervention: Basal infusion vs. bolus doses comparison
Number of subjects: 11
Study 18349213 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. granisetron 1 mg
Number of subjects: 40
Study 18349213 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 40
Study 16531384 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-only CPR (COCPR)
Number of subjects: 50
Study 16531384 — intervention group
Group type: COMPARATOR
Intervention: Traditional CPR (TCPR)
Number of subjects: 50
Study 14711749 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 1380
Study 11152365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for unruptured aneurysms
Number of subjects: 79
Study 11152365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for Grade 1 to 3 subarachnoid hemorrhage
Number of subjects: 79
Study 11152365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for Grade 4 or 5 subarachnoid hemorrhage
Number of subjects: 79
Study 9418686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg
Number of subjects: 33
Study 9418686 — intervention group
Group type: COMPARATOR
Intervention: No ovulation‐induction drugs (spontaneous group)
Number of subjects: 33
Study 7516915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 4 g/m2 plus G-CSF (5 or 10 micrograms/kg)
Number of subjects: 9
Study 2963647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilat ointment (active treatment)
Number of subjects: 0
Study 2963647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 30317947 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with β-glucans from Ganoderma lucidum
Number of subjects: 0
Study 30317947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25758041 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-enriched diet
Number of subjects: 26
Study 25758041 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 26
Study 23928749 — intervention group
Group type: EXPERIMENTAL
Intervention: In control: No alcohol! intervention
Number of subjects: 213
Study 23928749 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 213
Study 22205355 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with an angiotensin-converting inhibitor and receptor blocker
Number of subjects: 1044
Study 22205355 — intervention group
Group type: COMPARATOR
Intervention: Inhibitor alone
Number of subjects: 1044
Study 22205355 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitor-blocker treatment
Number of subjects: 1044
Study 22205355 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 1044
Study 22205355 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropomorphic measures
Number of subjects: 1044
Study 20452823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125-1.0 mg three times per day)
Number of subjects: 287
Study 20452823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 18665164 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg m(‐2) two times daily on days 1‐14 every 3 weeks
Number of subjects: 96
Study 18665164 — intervention group
Group type: COMPARATOR
Intervention: S-1 40‐60 mg two times daily according to body surface area on days 1‐28 every 6 weeks
Number of subjects: 96
Study 15567880 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (2 mg/2 ml, 1 mg/ml, 0.5 mg/ml, 0.5 mg/0.5 ml or 0.25 mg/ml)
Number of subjects: 144
Study 12759654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose multidetector CT (30 mA protocol)
Number of subjects: 10
Study 12759654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose multidetector CT (10 mA protocol)
Number of subjects: 10
Study 12759654 — intervention group
Group type: COMPARATOR
Intervention: Standard two view chest examination
Number of subjects: 10
Study 10760555 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 10706
Study 10760555 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 10706
Study 10760555 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (TCA)
Number of subjects: 10706
Study 10760555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (SSRI)
Number of subjects: 10706
Study 10760555 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin (TCA)
Number of subjects: 10706
Study 9233976 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 36
Study 9233976 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 36
Study 9233976 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study 8392032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated bipolar hemiarthroplasty
Number of subjects: 82
Study 8392032 — intervention group
Group type: COMPARATOR
Intervention: Uncemented bipolar prosthesis
Number of subjects: 82
Study 3526155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 550
Study 3526155 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (cephalothin, gentamicin, and carbenicillin)
Number of subjects: 550
Study 31907104 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (E)
Number of subjects: 1152
Study 31907104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1152
Study 31907104 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (M)
Number of subjects: 1152
Study 31907104 — intervention group
Group type: COMPARATOR
Intervention: Screening positive (S)
Number of subjects: 1152
Study 31907104 — intervention group
Group type: COMPARATOR
Intervention: Screening negative (N)
Number of subjects: 1152
Study 31050078 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day antibiotic treatment
Number of subjects: 33745
Study 31050078 — intervention group
Group type: COMPARATOR
Intervention: 7-day antibiotic treatment
Number of subjects: 33745
Study 28681388 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (NTZ) treatment
Number of subjects: 0
Study 28681388 — intervention group
Group type: COMPARATOR
Intervention: Control group (NTZ-ctr)
Number of subjects: 0
Study 24931061 — intervention group
Group type: EXPERIMENTAL
Intervention: One MetS-like component
Number of subjects: 6426
Study 24931061 — intervention group
Group type: EXPERIMENTAL
Intervention: Two MetS-like components
Number of subjects: 6426
Study 24931061 — intervention group
Group type: EXPERIMENTAL
Intervention: Three to four MetS-like components
Number of subjects: 6426
Study 22733406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular low-energy laser irradiation (λ=808 nm) during PCI
Number of subjects: 101
Study 22733406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser irradiation)
Number of subjects: 101
Study 21316267 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg/day
Number of subjects: 31
Study 21316267 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine-CR (CBZ-CR) 400 mg/day
Number of subjects: 31
Study 19168111 — intervention group
Group type: EXPERIMENTAL
Intervention: PncCRM vaccine
Number of subjects: 1662
Study 19168111 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 1662
Study 16889453 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200-800 mg/day)
Number of subjects: 673
Study 16889453 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (2-8 mg/day)
Number of subjects: 673
Study 16889453 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 673
Study 16889453 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 673
Study 16889453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 673
Study 14770380 — intervention group
Group type: EXPERIMENTAL
Intervention: isopropyl alcohol
Number of subjects: 33
Study 14770380 — intervention group
Group type: EXPERIMENTAL
Intervention: oil of peppermint
Number of subjects: 33
Study 14770380 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 33
Study 14770380 — intervention group
Group type: EXPERIMENTAL
Intervention: overall satisfaction with postoperative nausea management
Number of subjects: 33
Study 11526664 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different programs for drunken driving offenders
Number of subjects: 912
Study 9683300 — intervention group
Group type: EXPERIMENTAL
Intervention: oral clodronate 1600 mg daily for 3 years
Number of subjects: 206
Study 9683300 — intervention group
Group type: COMPARATOR
Intervention: control group (no clodronate)
Number of subjects: 206
Study 9683300 — intervention group
Group type: EXPERIMENTAL
Intervention: changes in PINP levels at 12 months
Number of subjects: 206
Study 9683300 — intervention group
Group type: EXPERIMENTAL
Intervention: changes in PINP and BMD
Number of subjects: 206
Study 9683300 — intervention group
Group type: EXPERIMENTAL
Intervention: ICTP and BMD changes
Number of subjects: 206
Study 7831070 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS) with a frequency of 100 Hz and peak-to-peak amplitude of 1 mm
Number of subjects: 66
Study 7831070 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS) with a frequency of 100 Hz and peak-to-peak amplitude of 2.5 mm
Number of subjects: 66
Study 7831070 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS) with a frequency of 100 Hz and peak-to-peak amplitude of 2.5 mm in population II
Number of subjects: 66
Study 2962321 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 5,000 International units per liter added to warm isotonic Ringer's lactate solution
Number of subjects: 92
Study 2962321 — intervention group
Group type: COMPARATOR
Intervention: No heparin added to warm isotonic Ringer's lactate solution
Number of subjects: 92
Study 31764194 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time Effort Driven ventilator management (REDvent)
Number of subjects: 0
Study 30586732 — intervention group
Group type: EXPERIMENTAL
Intervention: mWellcare (mHealth system with electronic health record storage and electronic decision support)
Number of subjects: 3698
Study 30586732 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 3698
Study 30586732 — intervention group
Group type: EXPERIMENTAL
Intervention: mWellcare
Number of subjects: 3698
Study 28430340 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic intracorporeal lithotripsy in gas (СО2) medium
Number of subjects: 60
Study 28430340 — intervention group
Group type: COMPARATOR
Intervention: Contact ureterolithotripsy in 0.9% NaCL medium (Control)
Number of subjects: 60
Study 25488181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 18
Study 25488181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral intervention involving contact with the target group
Number of subjects: 18
Study 25488181 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 18
Study 23761104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion of 30 g/150 mL water plus 3 g 3‐O‐methylglucose (3‐OMG)
Number of subjects: 27
Study 23761104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion of 30 g/150 mL water plus 3 g 3‐OMG
Number of subjects: 27
Study 23761104 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects during hyperglycemia
Number of subjects: 27
Study 23761104 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients during acute hyperglycemia
Number of subjects: 27
Study 22164503 — intervention group
Group type: EXPERIMENTAL
Intervention: Anluo Huaxian Wan
Number of subjects: 120
Study 22164503 — intervention group
Group type: COMPARATOR
Intervention: Routine liver protection drugs
Number of subjects: 120
Study 19407949 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular points sticking-pressing (APSP), pellets pressed 4 times daily
Number of subjects: 116
Study 19407949 — intervention group
Group type: COMPARATOR
Intervention: Control group (lactation to meet infant demand)
Number of subjects: 116
Study 19407949 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular points sticking-pressing (APSP)
Number of subjects: 116
Study 17083414 — intervention group
Group type: EXPERIMENTAL
Intervention: PALSA intervention training program for nurse trainers
Number of subjects: 0
Study 15241828 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy
Number of subjects: 286
Study 15241828 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 286
Study 15241828 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 286
Study 11250623 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire osteosynthesis with 8 weeks of maxillomandibular fixation
Number of subjects: 127
Study 11250623 — intervention group
Group type: COMPARATOR
Intervention: Rigid internal fixation
Number of subjects: 127
Study 9431616 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental transpedicular instrumentation
Number of subjects: 76
Study 9431616 — intervention group
Group type: COMPARATOR
Intervention: Noninstrumented group
Number of subjects: 76
Study 9431616 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall successful fusion
Number of subjects: 76
Study 7781464 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (7 micrograms/kg) during active gas infusion
Number of subjects: 20
Study 7781464 — intervention group
Group type: COMPARATOR
Intervention: Placebo during active gas infusion
Number of subjects: 20
Study 7781464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham gas administration
Number of subjects: 20
Study 7781464 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gas infusion
Number of subjects: 20
Study 2146577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 3 x 8 mg/day for a maximum of 10 cycles
Number of subjects: 40
Study 356241 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone (900 mg daily)
Number of subjects: 60
Study 356241 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg daily)
Number of subjects: 60
Study 356241 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone
Number of subjects: 60
Study 356241 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 60
Study 30129973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of vitamin C-rich fruit in regular meals
Number of subjects: 0
Study 30129973 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28527564 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri- and postoperative antibiotic prophylaxis (POAP) from the day of operation until the fifth day postoperatively
Number of subjects: 75
Study 28527564 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis (PEAP) only
Number of subjects: 75
Study 28527564 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis and increased local antiseptic care (PAPAC)
Number of subjects: 75
Study 24350597 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose endurance training (MOD, 300 kcal/day)
Number of subjects: 50
Study 24350597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose endurance training (HIGH, 600 kcal/day)
Number of subjects: 50
Study 24350597 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 50
Study 24118700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60
Study 24118700 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 60
Study 22938147 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of pulpally involved primary teeth (Group A)
Number of subjects: 164
Study 22938147 — intervention group
Group type: COMPARATOR
Intervention: Untreated children (Group B)
Number of subjects: 164
Study 20455886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (60,000 IU D3/week for 8 weeks followed by 60,000 IU/month for 4 months) with 1 g of elemental calcium daily
Number of subjects: 40
Study 20455886 — intervention group
Group type: COMPARATOR
Intervention: Dual placebos
Number of subjects: 40
Study 16575494 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (100 IU salmon calcitonin)
Number of subjects: 30
Study 16575494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16239760 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (exact dosage and duration not specified)
Number of subjects: 160
Study 16239760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 11872681 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15
Study 11872681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10463251 — intervention group
Group type: EXPERIMENTAL
Intervention: Iprazochrome 15 mg daily in three equal doses for eight weeks
Number of subjects: 44
Study 10463251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9017568 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 500
Study 9017568 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of treatment on a fee-for-service basis
Number of subjects: 500
Study 9017568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer to another treatment provider
Number of subjects: 500